TEVANYSEPharmaceutical PreparationsUS GAAP · USD

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd. is a biopharmaceutical company built around a large global generics platform and a portfolio of branded innovative medicines. It operates through three regional segments — the United States, Europe and International Markets — and also sells active pharmaceutical ingredients, provides contract manufacturing services, and licenses products through its Medis affiliate.

Ask about the company
Revenue17.3bn USD
+4.3 %y/y
Operating profit (EBIT)2,157m USD
+811.9 %y/y
EBIT margin12.5%
+14.3 ppy/y
Net income1,410m USD
+186.0 %y/y
Free cash flow1,649m USD
+32.2 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-505101520bn USD2020: 16.7 bn USD2020: EBIT -3.6 bn USD20202021: 15.9 bn USD2021: EBIT 1.7 bn USD20212022: 14.9 bn USD2022: EBIT -2.2 bn USD20222023: 15.8 bn USD2023: EBIT 0.43 bn USD20232024: 16.5 bn USD2024: EBIT -0.30 bn USD20242025: 17.3 bn USD2025: EBIT 2.2 bn USD202517.32.2
RevenueOperating profit (EBIT)
Ask Clarifo about Teva Pharmaceutical Industries Limited

Business

Share of revenue
Generic medicines55 %

Off-patent prescription products sold across multiple dosage forms and therapeutic areas.

Innovative medicines25 %

Branded specialty therapies focused on CNS, migraine, MS, respiratory and oncology.

Biosimilars and OTC10 %

Biologic follow-on products and over-the-counter medicines sold in regional markets.

API and contract manufacturing5 %

Third-party active ingredient sales and manufacturing services.

Out-licensing and other activities5 %

Product licensing and affiliate-based commercialization activities.

Products

Reported · share of revenue
84.6%9.0%FY2025100 %
  • Products84.6 %
  • Distribution Service9.0 %
  • License3.9 %
  • Other2.5 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Teva sells primarily to wholesalers, retail drug chains, mail-order distributors, managed care purchasing organizations and hospitals. Its customer base differs by product type: generics are sold into large purchasing channels with strong bargaining power, while innovative medicines are sold through specialty and pharmacy distribution channels serving patients with chronic or complex conditions.

U.S. retail drug chains and wholesalers

Buy large volumes of generic medicines and some branded products for broad pharmacy distribution.

Managed care and buying groups

Influence formulary access, rebates and pricing for U.S. medicines.

Mail-order and specialty distributors

Purchase chronic and specialty therapies such as CNS and migraine products.

Hospitals and healthcare institutions

Buy injectable, inhaled and other hospital-administered products.

International pharmacy and healthcare channels

Buy generics, OTC and branded medicines across Europe and other markets.

Strategy

Teva’s strategy centers on growing its innovative portfolio while using its generics platform, global scale and regional operating structure to support access and lifecycle management. The company also emphasizes capital allocation toward higher-value activities and operational simplification to improve execution, supply reliability and cost efficiency.

Expand innovative medicinesMedium term

Branded specialty products provide differentiation beyond commoditized generics.

Protect and refresh the generics portfolioShort term

Generics remain the volume base and support broad market access.

Improve operating efficiencyShort term

A simpler cost structure helps fund R&D and commercial execution.

Broaden geographic executionMedium term

Regional diversification reduces dependence on any single market.

Geography

Teva is headquartered in Israel and operates across 57 markets, with major commercial presence in the United States, Europe and International Markets. The United States and Europe are the most important operating regions, while manufacturing, R&D and commercial activities are distributed globally to support local market access and supply reliability.

Risks

Teva is exposed to intense generic-drug competition, customer concentration and pricing pressure, especially in the United States where a few large buyers control much of the market. It also faces regulatory, litigation, cybersecurity and policy risks that can disrupt product approvals, commercialization and supply continuity.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Generic price erosion and competition1Customer concentration in the U.S.2Regulatory and compliance actions3Litigation and patent disputes4Cybersecurity and data security incidents5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Generic price erosion and competitionImpact: HighLikelihood: High

    Off-patent medicines face frequent entry from rival manufacturers and rapid pricing pressure.

    Exposure: Generic prescription medicines

  2. Customer concentration in the U.S.Impact: HighLikelihood: High

    A relatively small number of wholesalers, chains and buying groups account for a large share of sales.

    Exposure: United States generics

  3. Regulatory and compliance actionsImpact: HighLikelihood: High

    Pharmaceutical manufacturing and marketing are heavily regulated and noncompliance can trigger penalties or shutdowns.

    Exposure: Global manufacturing and approvals

  4. Litigation and patent disputesImpact: MediumLikelihood: High

    Product challenges, including COPAXONE-related disputes, can delay or limit commercialization.

    Exposure: Selected branded products

  5. Cybersecurity and data security incidentsImpact: MediumLikelihood: Medium

    IT disruption or data theft could interrupt operations and create liability.

    Exposure: Global systems and third-party vendors

Ask Clarifo about Teva Pharmaceutical Industries Limited

Accounting

Judgemental items
Revenue recognition and U.S. sales deductions

Gross sales are reduced by estimated rebates, chargebacks and allowances in the same period.

Impact: Affects reported net revenue and comparability across quarters

Contingencies and litigation reserves

Product disputes and regulatory matters require judgment on probable losses.

Impact: Can create volatile charges and balance-sheet liabilities

Impairment of property, plant and equipment

Manufacturing assets must be tested if utilization or economics weaken.

Impact: May lead to non-cash write-downs

Income taxes

Deferred tax assets, valuation allowances and uncertain tax positions require estimates.

Impact: Can materially change net income and equity

Hedging and foreign exchange

Regional operations and cross-border cash flows create currency exposure.

Impact: Can affect operating results and comprehensive income

Similar listed companies

Publicly listed companies with a comparable business focus.

MediciNova, Inc

MNOV · Pharmaceutical Preparations

Veeva Systems Inc

VEEV · Services-Prepackaged Software

Takeda Pharmaceutical Company Limited

TAK · Pharmaceutical Preparations

Elite Pharmaceuticals Inc /NV/

ELTP · Pharmaceutical Preparations

SIGA Technologies Inc

SIGA · Pharmaceutical Preparations

Gilead Sciences, Inc

GILD · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026

Teva Pharmaceutical Industries Limited (TEVA) Revenue, Earnings & Financials 2025 – Clarifo